From Data Management to Data Science: Reimagining Clinical Data in Pharma R&D

Figure 1: CDM Evolution Timeline

In this era of rapid digital transformation, the evolution of CDM into CDS is no longer optional; it is an imperative. With rapid advancements in technology, organizations must align their systems, platforms, and workforce capabilities to accelerate data-driven decisions and outcomes into real-world actions. CDS leverages an upskilled workforce operating on modern data platforms, supported by AI in CDM technologies, to integrate data sources in real time, supporting continuous analytics, and using an automated workflow. Unlike traditional retrospective reactive models, it enables proactive oversight of diverse data streams, driving better decisions, sustained competitive advantage, and faster drug development.

FCCs, particularly those specializing in CDS, have emerged as the ideal strategic partners for this transformation. Purpose-built to be domain-specific, agile, and AI-enabled, FCCs unite specialized talent, modular AI agents, and flexible partner ecosystems to deliver high-value outcomes across the clinical lifecycle. They offer the scalability, innovation, and speed required for modern data management in clinical research, enabling organizations to pivot quickly as trial needs evolve.

This report examines the top operational priorities of CDM leaders, along with the technology enablers and process enhancements they are implementing to enhance the CDM function's strategic value and operational excellence. It explores how AI in CDM is reshaping traditional workflows and is creating new opportunities for data science in clinical research applications. It also highlights why transitioning from traditional CDM to CDS is essential for achieving these goals at scale. Additionally, the report presents a strategic framework showing how FCCs can act as catalysts for seamless CDS integration, bringing specialized expertise, advanced technologies, and proven methodologies that strengthen existing CDM infrastructure, reduce transformation risks, and accelerate adoption. Understanding current priorities and investment patterns in data science for clinical trials allows for the foundation for successful CDS adoption, enabling organizations to effectively balance traditional CDM enhancements with emerging technological capabilities.

Current CDM Priorities—Technology Adoption and Workforce Transformation

The CDM industry is at a strategic inflection point where traditional data standardization priorities now intersect with GenAI-driven transformation. The emergence of data science in clinical research has created unprecedented opportunities to reimagine how pharmaceutical companies approach trial design, execution, and regulatory compliance. Sponsors must move beyond conventional controls- process maps, SLAs, and staff augmentation- to adopt platform-level strategies that embed standardization, interoperability, and governance by design. The integration of AI in CDM requires a fundamental shift from reactive data processing to predictive, intelligence-driven operations. This transformation follows a clear pattern across the industry: organizations first tackle foundational data standardization challenges, then commit significant technology investments to GenAI solutions while recognizing that human governance remains essential.

FCCs have become instrumental in this evolution, providing the specialized expertise required to implement advanced data science clinical trial methodologies. This drives parallel workforce upskilling initiatives and ultimately reshapes outsourcing strategies from cost-based models to capability-driven partnerships with FCCs that specialize in CDS. The following analysis, largely drawn from our CDM industry survey report, with insights from 100 CDM leaders, and the AI in Biotech R&D report, respectively, examines each of these interconnected priorities and their implications for CDM transformation.

Data Standardization Dominates CDM Leadership Priorities

53% of CDM leaders identify SDTM mapping and domain creation as their top priority, followed by 48% who emphasize faster database go-live, and 42% who cite expedited electronic Case Report Form (eCRF creation). These focus areas reflect the growing importance of data science in clinical research, where standardized data structures enable advanced analytics and AI-driven insights. These focus areas reflect a shift toward removing foundational delays in the data pipeline. The implementation of robust data management in clinical research frameworks is essential for supporting downstream AI applications and automated decision-making processes. Improvements here unlock broader trial efficiencies, accelerating downstream activities such as statistical programming and submission preparation.

Figure 2: Top CDM Leadership Priorities (Source: Indegene 2024 survey on 100 CDM leaders in the US and EU)

Technology Investment Reaches Majority Budget Allocation

Many CDM functions are allocating over half of their budgets (56%) to technology investments, with European firms reaching 60%. This significant investment reflects the industry's commitment to integrating AI in CDM and advancing data science clinical trials capabilities. While 75% report using AI or ML to improve data quality, advanced adoption remains below 10% in most CDM functional areas. Sponsors are increasingly partnering with organizations to access specialized expertise in data science in clinical research and accelerate their AI transformation initiatives. Most investments target task automation, real-time data integration, and AI-driven protocol design optimization, rather than building integrated AI platforms.

GenAI Adoption Shows Strong Intent with Measured Implementation

Over 75% of CDM leaders cite efficiency as the primary driver for GenAI adoption. The application of AI in CDM extends beyond efficiency to encompass predictive analytics, automated anomaly detection, and intelligent data quality monitoring. Yet most organizations remain in pilot or limited-use phases. Table Listing Figure (TLF) generation (79%), database go-live acceleration (68%), and data standardization (60%) are the most common GenAI use cases. These applications demonstrate how data science clinical trials methodology can transform traditional workflows and create new value streams. More than 30% aim to scale these applications within 6 - 12 months. However, regulatory uncertainty continues to delay broader deployment. FCCs with specialized expertise in CDS are helping organizations navigate these regulatory challenges while maintaining compliance standards.

Figure 3: Top GenAI Use Cases in CDM (Source: Indegene 2024 survey on 100 CDM leaders in the US and EU)

AI Requires Human Governance and Validation

AI in CDM is not designed to replace human expertise, but to enhance it. The successful implementation of data science in clinical research requires a hybrid approach that combines algorithmic efficiency with human judgment and domain expertise. Generative tools for protocol digitization and TLF creation require oversight by professionals who understand both AI model/algorithm behavior and regulatory standards. Sponsors must establish human-in-the-loop governance roles, including AI validators, prompt engineers, and metadata curators as integral parts of core data management in clinical research operations. FCCs provide access to these specialized roles, offering expertise that may be difficult to develop internally.

Workforce Upskilling Parallels Technology Investment Strategy

51% of workforce development budgets are now focused on technology training, including AI/ML integration. This investment in human capital reflects the evolving nature of CDM, where traditional data processing skills must be enhanced with data science in clinical research competencies. Electronic Data Capture (EDC) systems, Clinical programming, Clinical Data Interchange Standards Consortium (CDISC) standards (SDTM and ADaM) remain the top priority, followed by statistical and data science competencies. The integration of AI in CDM requires professionals who can bridge clinical domain knowledge with advanced analytics and technology expertise. This signals a structural shift where AI literacy is now essential to CDS roles, alongside traditional CDM expertise. Organizations are leveraging FCCs to access pre-trained talent pools and accelerate their workforce transformation initiatives.

Strategic Outsourcing Evolves Beyond Cost Reduction to AI Capability Access

Between 25 – 75% of SDTM and AdaM creation is now outsourced, along with comparable levels of TLF programming. Notably, 70% of sponsors cite AI/ML capability as a key driver in outsourcing decisions. This shift toward capability-based partnerships with FCCs reflects the strategic importance of data science clinical trials expertise in maintaining a competitive advantage. This marks a shift from cost-based models to accessing skills in specialized AI tools and therapeutic knowledge that are difficult to build in-house. FCCs specializing in CDS offer the depth of expertise required to implement sophisticated data science in clinical research applications. The trend is most visible in areas like data standardization and regulatory compliance, where both technical precision and scalability are critical. Organizations are increasingly viewing partnerships with specialized FCCs as essential for accessing advanced AI in CDM capabilities.

While these priorities and investments signal industry readiness for change, successfully transitioning from CDM to CDS requires more than technology adoption alone. Organizations must fundamentally reimagine their operating models, governance structures, and capability frameworks. CDS provides this comprehensive framework, transforming how data management in clinical research creates value across the enterprise. The following section outlines the essential components for implementing CDS at an enterprise scale.

Implementing CDS—Framework and Requirements

Within a life sciences company, while CDM focuses on data collection, cleaning, and database management, CDS adds value by applying advanced analytics and technology throughout the clinical development pipeline to elevate data quality, streamline processes, and robustly support evidence-based decisions. The evolution from traditional data management in clinical research to advanced CDS represents a paradigm shift that enables pharmaceutical companies to harness the full potential of their clinical data assets. By embedding AI/ML capabilities and predictive analytics into clinical trials, sponsors and CROs can accelerate protocol design, reduce data cleaning timelines, take informed decisions, and conduct post-hoc analysis using RWD and historical insights, and real-time surveillance. The implementation of data science clinical trials methodologies transforms how organizations approach trial design, patient recruitment, and regulatory submissions. CDS defines how data flows and transforms, and how associated assets, such as mappings, metadata models, and validation frameworks, can be reused across trials and platforms.

Well-defined CDS processes, supported by AI in CDM technologies, streamline trial conduct and reduce manual intervention. This requires aligned standards, reusable transformation logic, and technology-enhanced pipelines for ingestion and processing of data. FCCs specializing in CDS provide the infrastructure and expertise needed to implement these sophisticated data sciences in clinical research frameworks at scale. This helps them identify trends and risks early in the process, improve database lock efficiency, establish a more streamlined, proactive approach to clinical trial management, and enhance regulatory submissions with structured, high-quality data narratives that demonstrate both scientific rigor and operational excellence.

Figure 4: Added Value of CDS to the CDM Function

To support CDS at scale, organizations must systematize the integration of systems, platforms, and processes. The successful implementation of data science for clinical trials requires a comprehensive approach that encompasses technology infrastructure, governance frameworks, and specialized expertise. Implementation starts with a reference architecture, progresses through intelligent automation, and culminates in scalable analytics capabilities. Without this foundation, data will remain siloed, and many of the AI in CDM use cases will stay limited to exploratory pilots.

As data management in clinical research becomes more complex and data-driven, teams must transition from pure task execution to insight generation to deal with the complexity. Skills in metadata stewardship, AI validation, and scientific interpretability have become essential for maintaining compliance and enabling strategic participation in data science in clinical research. FCCs offer access to professionals who possess these hybrid skills, combining clinical domain expertise with advanced data science and clinical trials competencies. Thus, it is important to recruit and develop professionals who understand both technical workflows and the scientific context of data management in clinical research.

CDS must scale without losing consistency. To support this, organizations must leverage the specialized expertise available through FCCs, which provide access to advanced AI in CDM technologies and proven implementation methodologies. Organizations must go beyond traditional CDM resourcing models and invest in purpose-built capability frameworks. Many CDS roles such as AI validators, data/metadata stewards, and algorithm creators and curators are niche today, they are becoming core to future-ready clinical data functions. Scaling CDS requires structured role definitions, dedicated training and upskilling programs, and integrated platforms that reduce manual effort and enable automation by design. FCCs provide access to these specialized roles and offer the scale required to implement data science in clinical research initiatives across multiple therapeutic areas and geographic regions. Organizations must establish centralized teams starting with Centers of Excellence as Proof Concepts to build repeatable CDS workflows, supported by standard operating procedures and reusable assets. Without such a systematic approach, CDS will remain limited to pilot programs and fragmented innovations.

Towards this transformation, many sponsors are moving away from fragmented CDM setups, where each study team works independently with its own standards and without learning from past studies. In contrast, centralized teams or Centers of Excellence bring CDM activities into a single, unified team using common processes and shared infrastructure. FCCs operating as federated models can maintain delivery across different locations while following the same concepts of data science applied to clinical trials along with standards and oversight. This approach improves quality, speed, and visibility. CDS teams leverage these centralized and/or federated models to standardize processes, automate recurring tasks, and track performance across studies while applying historical trial data to improve future study design.

CDS teams must be able to see and manage the full data process. Without proper infrastructure for data science in clinical research, intelligent automation becomes risky and may produce non-compliant outputs. Systems to track data collection, transformation, and usage throughout the trial lifecycle, data platforms that support robust metadata management, and programming tools that easily connect these platforms are the essential infrastructure requirements that ensure structure, meaning, and interoperability. FCCs provide the technological infrastructure and expertise needed to implement comprehensive AI in CDM solutions that meet regulatory requirements. Repositories are needed to store both working and final versions of datasets, with clear rules for access and updates.

Robust metadata infrastructure is a critical enabler for CDS to manage data efficiently across data science for clinical trials. While some CDS capabilities, for example, exploratory analytics, AI-driven document summarization, and feasibility assessments using real-world data can operate in less structured environments, sustained impact and automation require consistent metadata management. The implementation of standardized metadata frameworks enables FCCs to deliver consistent, high-quality data management in clinical research services across multiple sponsors and therapeutic areas. Without clear ownership and structure, metadata fragmentation creates barriers to reuse and limits automation potential, particularly for submission-ready outputs. For instance, when one team defines 'adverse event' differently than another, downstream integration challenges multiply. CDS teams must define and maintain metadata standards using common templates, controlled terminology, and shared repositories. When managed centrally through partnerships with specialized capability centers, these standards enable cross-functional collaboration across medical, biometrics, clinical operations, safety, and regulatory teams while creating the foundation for scalable AI in CDM implementation.

FCCs as Catalysts for CDS Transformation

The transition to CDS represents a fundamental shift in how data management in clinical research creates value for overall clinical operations. FCCs specializing in CDS have emerged as essential enablers of this transformation, providing the specialized expertise, technological infrastructure, and scale required to implement advanced data science methodologies in clinical trials. Service providers who successfully position themselves as strategic innovation partners, combining deep domain expertise with cutting-edge AI in CDM capabilities, will secure long-term partnerships and help sponsors drive the future of clinical trials. These centers serve as innovation hubs that bridge the gap between traditional CDM and next-generation CDS applications. Here’s how they can drive this transformation: Most sponsors lack the resources, expertise, and infrastructure to build comprehensive CDS capabilities internally while maintaining current operations. FCCs help sponsors move from transactional data management in clinical research activities to capability-based strategic partnerships. These specialized centers bring structure, sustainability, and scale to CDS operations by leveraging AI in CDM and technology-based solutions tailored for data science clinical trials. They anchor their CDS partnership models on four critical capabilities: technology integration, regulatory expertise, clinical domain knowledge, and talent development to support the shift toward AI-enabled CDM operations.

Technology Integration and Platform Expertise

FCCs must be able to work across the sponsor’s data platforms in a manner which is beyond managing tasks. Within the global capability center framework, this includes building metadata-driven EDC systems, implementing AI in CDM solutions for intelligent automation of SDTM and AdaM processes, and building and executing in an analytics environment which allows for real-time data science in clinical research insights. Within the FCC framework, this includes building metadata-driven EDC systems, AI based intelligent automation for SDTM and AdaM, and building and executing in an analytics environment which allows for real-time insights. Expertise in automation tools, data lakes, and orchestration platforms is essential for implementing comprehensive data science clinical trials solutions. FCCs also integrate AI in CDM use cases, such as TLF generation and document review, into validated workflows, creating intelligent automation. Their role extends beyond execution to embedding CDS technologies into everyday delivery and creating reusable frameworks that can be scaled across multiple sponsors and therapeutic areas.

Regulatory and Compliance Expertise

FCCs operate in regulated environments and must maintain expertise in both traditional CDM compliance requirements and emerging regulations governing AI in CDM applications. To support CDS functions, they must apply consistent quality controls, maintain audit trails, and understand the data expectations of global regulatory agencies. This includes CDISC compliance, AI output validation for data science for clinical trials, data privacy safeguards, and adherence to emerging AI regulations that govern data science in clinical research applications. FCC teams must proactively identify and mitigate risks across metadata handling, data transformation, reporting, and submission preparation. Regulatory knowledge is not optional but is foundational to scalable CDS delivery by FCCs, particularly as AI in CDM technologies continue to evolve.

Domain Expertise Beyond Traditional CDM

Supporting CDS requires more than technical execution; FCCs must build comprehensive domain understanding that spans traditional data management in clinical research and advanced data science for clinical trials methodologies. FCCs must build domain understanding across study design, therapeutic areas, clinical operations and regulatory requirements. This alignment ensures that data science in clinical research workflows support trial objectives and evidence generation strategies while maximizing the value derived from AI in CDM investments. These teams must grasp protocol rationale, visit schedules, and efficacy/safety endpoints, moving beyond simple data validation to contextual understanding that enables CDS applications. This contextual knowledge allows these centers to support insights beyond clean datasets. As CDS expands, this broader expertise from partnerships with specialized FCCs becomes a key differentiator in delivering successful data science for clinical trials.

Talent Strategy

FCCs must invest in talent that can grow with the CDS model. This includes hybrid roles that combine technical, clinical, and analytical skills specifically designed for data science in clinical research and AI in CDM applications. Training programs in these centers focus on metadata literacy, AI in CDM / Technology readiness, and regulatory thinking required for successful data science clinical trials implementation. These centers also largely have clear career paths, role definitions, and performance metrics to retain high performers in the evolving CDS landscape. A well-defined talent strategy ensures consistent, scalable CDS capability delivery across multiple sponsors and therapeutic areas. FCCs that invest in people, not just platforms, will become long-term CDS transformation partners. The convergence of these capabilities – technology, regulatory expertise, domain knowledge, and talent- positions FCCs as essential enablers of the CDM to CDS transition. As the industry moves forward, three critical insights emerge from this transformation journey.

Key Takeaways

Act Now on the Strategic Imperative

Organizations must immediately begin the CDM to CDS transition while addressing foundational data challenges. While establishing protocol and metadata standardization for data science for clinical trials is a long-term goal, sponsors can accelerate progress by partnering with specialized FCCs that provide immediate access to AI in CDM expertise and proven implementation frameworks. Organizations can accelerate progress by first deploying diagnostic tools that highlight and bring out non-standardization patterns and process gaps. These insights will allow organizations to prioritize automation opportunities and pilot CDS use cases, such as AI-driven SDTM mapping or intelligent query management, even before full standardization is achieved. FCCs can provide the specialized expertise needed to implement the data science concepts in clinical research initiatives while internal teams focus on strategic priorities. This approach enables early wins while laying the groundwork for broader CDS integration.

Mandate Leadership and Capability Transformation

Every organization must urgently prioritize the development of next-generation leadership and workforce capabilities to sustain the shift from CDM to CDS. Appoint leaders who can operate at the intersection of clinical science, AI in CDM, and regulatory strategy as this is no longer optional but core to successful data science for clinical trials transformation. Build hybrid roles that blend technical, statistical, and therapeutic expertise, such as Clinical Data Scientists, Metadata Engineers, and AI Validation Leads specializing in data science in clinical research applications. Establish formal AI governance functions, including model validators and prompt engineers with expertise in AI in CDM, embedded within delivery teams. Make AI literacy and regulatory fluency mandatory for all CDS roles through structured, ongoing training programs offered by specialized FCCs. Clearly defined career paths, role mandates, and performance expectations must be built now to ensure capability continuity and accelerate CDS maturity across data science clinical trials initiatives.

Partner Strategically for Acceleration

Engage FCCs specializing in CDS now to handle technical implementation complexity while internal teams focus on core scientific activities, such as protocol design, data interpretation, and therapeutic strategy. Select FCCs based on their demonstrated expertise in AI in CDM, proven data science clinical trials frameworks, and ability to rapidly deploy solutions for protocol optimization, automated data standardization, and intelligent query management. Evaluate these centers on their CDS innovation pipeline, regulatory expertise in data science in clinical research, and talent development programs rather than cost alone. Transform vendor relationships from transactional contracts to strategic partnerships with FCCs that offer shared success metrics and joint investment in CDS capabilities.

Figure 5: CDS Transformation Roadmap: Three-Phase Implementation Strategy

Accelerating Drug Development: The CDS Imperative for Pharmaceutical Excellence

The shift from CDM to CDS is imperative to accelerate efficiencies in drug development, enhance data quality, and ensure regulatory compliance. FCCs provide the specialized expertise, technological infrastructure, and scale required to implement comprehensive data science driven solutions for clinical trials. With the right combination of leadership commitment, strategic partnerships with specialized FCCs, and systematic implementation, the journey from traditional data management in clinical research to advanced CDS can begin immediately.